Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.48 |
| ▸ | ADH1A | P07327 | 4/20 | 0.48 |
| ▸ | ADH7 | P40394 | 3/20 | 0.48 |
| ▸ | ADH1C | P00326 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ADH4 | P08319 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24798076 | 0.87 | ADH1B (0.39) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL16659377 | 0.87 | ADH1B (0.44) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL22124595 | 0.87 | — | — | |
| SCHEMBL3465685 | 0.87 | — | — | |
| SCHEMBL404646 | 0.87 | — | — | |
| SCHEMBL23251714 | 0.85 | ADH1B (0.37) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL24798067 | 0.85 | ADH1B (0.37) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL24205319 | 0.85 | ADH1B (0.37) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL20845975 | 0.85 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL22419958 | 0.85 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129118-A1 | PHYTOSPHINGOSINE DERIVATIVES AS ADJUVANTS IN IMMUNE STIMULATION | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-04-27 | — | — | US | disclosed |
| WO-2015055406-A1 | METHOD FOR SEPARATING N,N,N'-TRIMETHYLBISAMINOETHYLETHER AND/OR N,N-DIMETHYLBISAMINOETHYLETHER FROM A MIXTURE | HUNTSMAN CORPORATION HUNGARY ZRT. (HU) | 2015-04-23 | — | — | WO | disclosed |
| EP-0078266-B1 | CROSS-LINKABLE POLYMER COMPOSITION SOLUBLE IN AN AQUEOUS MEDIUM, PREPARATION AND UTILIZATION THEREOF | CASSELLA Aktiengesellschaft (DE) | 1985-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129118-A1 | PHYTOSPHINGOSINE DERIVATIVES AS ADJUVANTS IN IMMUNE STIMULATION | UGCG, PA2G4, IL4 | ADH1B 4320/4885ADH1A 3974/4885ADH7 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.